Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Multicenter, Masked, Parrallel-Group, Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 (3 Doses: 0.021%, 0.042%, and 0.065%) vs. Latanoprost 0.005% in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Conditions
Interventions
NCX 470
Latanoprost 0.005%
Locations
1
United States
Texan Eye
Austin, Texas, United States
Start Date
August 1, 2018
Primary Completion Date
August 23, 2019
Completion Date
August 23, 2019
Last Updated
June 18, 2023
NCT06289491
NCT05885022
NCT03870230
NCT06201455
NCT05624398
NCT05405868
Lead Sponsor
Nicox Ophthalmics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions